Structural Intervention

About

Valve replacement surgery can be an effective, lifesaving treatment option for people with aortic or mitral valve diseases.

Aortic valve replacement is often required in older patients but the surgical risk is often extremely high. Transcatheter aortic valve implantation (TAVI) is an established therapy for intermediate and high surgical risk patients with symptomatic severe aortic valve stenosis.

Approximately 1.8% of the US population has mitral valve disease, and an estimated 106,000 surgeries per year are for the treatment of valvular heart disease. The durability of surgical mitral valve repairs and replacement are limited. There is a 25% rate of significant mitral regurgitation recurrence in surgical repairs at 2 years and a 44% rate of primary valvular failure at 15 years, leaving the patient with either symptomatic mitral regurgitation, stenosis or both.

Articles

The Role and Potential of 3D Echocardiography in the Assessment of Mitral Regurgitation

Citation:

European Cardiology 2012;8(3):165–70

Embolic Protection

Citation:

European Cardiovascular Disease 2007;3(1):89–90

Transcatheter Aortic Valve Implantation in High-risk Patients with Severe Aortic Stenosis

Citation:

European Cardiology 2012;8(2):115-9

Intracoronary Thrombectomy During Percutaneous Coronary Intervention in Acute Myocardial Infarction - Technology Showcase or True Need?

Citation:

European Cardiology 2005;1(1):44-5